TY  - JOUR

T1  - A phase III, randomized, open label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine+cisplatin (G+C) for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (MIBC) (NIAGARA).

JO  - Journal of Clinical Oncology

PY  - 2019/05/20

AU  - Powles T

AU  - Meeks JJ

AU  - Galsky MD

AU  - Van Der Heijden MS

AU  - Nishiyama H

AU  - Al-Ahmadie H

AU  - Gupta AK

AU  - Ye J

AU  - Donegan SE

AU  - Ghiorghiu DC

AU  - Ferro S et al

ED  - 

DO  - DOI: 10.1200/jco.2019.37.15_suppl.tps4592

PB  - American Society of Clinical Oncology (ASCO)

VL  - 37

IS  - 15_suppl

SP  - TPS4592

EP  - TPS4592

Y2  - 2024/12/22

ER  -